Early Briefing and Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc.

LONDON, October 22, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

On Monday, October 21, 2013, the S&P 500 ended the day at 1,744.66, up 0.01%; the Dow Jones Industrial Average closed at 15,392.20, down 0.05%; while the NASDAQ Composite finished at 3,920.05, up 0.15%. Shares in the healthcare sector ended mostly lower, even as the broader market finished on a mixed note. The major movers in the sector included Dendreon Corporation (NASDAQ: DNDN), Stryker Corporation (NYSE: SYK), Novartis AG (NYSE: NVS), and Repros Therapeutics Inc. (NASDAQ: RPRX). AAAResearchReports.com has released free charting and technical research on these aforementioned companies. Register to read these reports at:

http://www.aaaresearchreports.com/register/  

On Monday, Dendreon Corp.'s stock declined to close at $2.40, down 1.64% from the previous day's closing price of $2.44. The company's shares fluctuated between $2.39 and $2.51 during the trading session. A total of 3.39 million shares were traded, which is below the daily average volume of 4.57 million. The company's shares are down 11.28% in the previous three trading sessions, underperforming the S&P 500, which has gained 1.34% during the same period. Furthermore, Dendreon Corp.'s stock is trading below its 50-day and 200-day moving averages of $2.94 and $4.43, respectively. Sign up for free report on DNDN at:

http://www.AAAResearchReports.com/DNDN102213.pdf

Shares in Stryker Corp. edged lower on Monday, reversing some of the gains from the previous trading session. The company's shares ended the day 0.41% lower at $73.16 after oscillating between $72.92 and $73.45 during the trading session. A total of 1.10 million shares were traded, which is below the daily average volume of 1.27 million. Despite Monday's losses, the company's stock is up 3.22% in the previous three months and 2.64% in the last one month, compared to a gain of 3.11% and 2.03% in the S&P 500 during the respective periods. Moreover, Stryker Corp.'s stock is trading near its 52-week high of $73.60 and also above its 50-day and 200-day moving averages of $69.20 and $66.50, respectively. SYK free technical report can be accessed by signing up at:

http://www.AAAResearchReports.com/SYK102213.pdf

Novartis AG's stock ended higher on Monday, even as the broader market fluctuated between gains and losses. The company's shares fluctuated between $74.72 and $75.34 before finishing the day 0.37% higher at $75.30. A total of 0.97 million shares were traded, which is below the daily average volume of 1.38 million. The company's shares have gained 1.78% in the previous three trading sessions and 3.76% in the last three months, outperforming the S&P 500, which has advanced 1.34% and 3.11% during the respective periods. Further, Novartis AG's stock is trading above its 50-day and 200-day moving averages of $75.00 and $71.85, respectively. A free report on NVS can be accessed by registering at:

http://www.AAAResearchReports.com/NVS102213.pdf

Repros Therapeutics Inc.'s stock plummeted on Monday, extending the losses from the previous trading session. The company's shares closed the day at $23.67, down 5.32%, after oscillating between $23.51 and $25.16 during the trading session. A total of 0.36 million shares were traded, which is below the daily average volume of 0.64 million. Despite Monday's losses, the company's shares have surged 14.13% in the previous three months, compared to a gain of 3.11% in the S&P 500 during the same period. Furthermore, Repros Therapeutics Inc.'s stock is trading above its 50-day and 200-day moving averages of $23.20 and $17.90, respectively. Register with AAA Research Reports and download research on RPRX for free at:

http://www.AAAResearchReports.com/RPRX102213.pdf

EDITOR NOTES:

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider represented by Ananya Ghosh, CFA, has only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

http://www.AAAResearchReports.com

SOURCE AAA Research Reports